Canaccord Genuity Maintains Buy on MapLight Therapeutics, Lowers Price Target to $24

Benzinga · 1d ago
Canaccord Genuity analyst Sumant Kulkarni maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $43 to $24.